公开(公告)号：US11357851B2

公开(公告)日：2022-06-14

申请号：US15774327

申请日：2016-11-09

Applicant: Novartis AG

Inventor： Shinji Hatakeyama ,  Ronenn Roubenoff ,  Estelle Trifilieff ,  Jerome Feige ,  Lloyd B. Klickstein

IPC: A61K39/395 ,  A61P21/00 ,  A61P35/00 ,  A61K33/243 ,  A61K31/436

Abstract: The present invention relates to myostatin antagonists, for the treatment of cancer cachexia, and cancer cachexia due to chemotherapeutic treatment. In particular, the myostatin antagonist bimagrumab was found to be beneficial in the treatment of cancer cachexia by reducing body weight loss. The present invention also relates to combinations and uses of a myostatin antagonist and an mTOR inhibitor for treating cancer cachexia by reducing, maintaining or increasing body weight loss or for use in treating age-related conditions.

公开(公告)号：US20190083473A1

公开(公告)日：2019-03-21

申请号：US16137360

申请日：2018-09-20

Applicant: Novartis AG

Inventor： Michael Badman ,  Lloyd B. Klickstein ,  Bryan Laffitte

IPC: A61K31/439 ,  A61K31/4748 ,  A61K31/497 ,  A61K31/426 ,  A61K31/422 ,  A61K31/506

Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using compounds of Formula (I) or (II). In particular, the invention provides for the use of compounds of Formula (I) or (II), or a stereoisomer, enantionmer or pharmaceutically acceptable salt thereof, for treating or preventing liver and gastrointestinal diseases.

公开(公告)号：US20140213622A1

公开(公告)日：2014-07-31

申请号：US14342813

申请日：2012-09-06

Applicant: NOVARTIS AG

Inventor： Ann Taylor ,  Lloyd B. Klickstein ,  Jeewan Thakur

IPC: A61K31/4196 ,  A61K9/48

CPC classification number: A61K31/4196 ,  A61K9/4833 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866

Abstract: The invention relates to low-dose pharmaceutical compositions comprising the aromatase inhibitor 4,4′[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile, as the active ingredient in a suitable carrier. The present invention also relates to a process for their preparation and to their use as therapeutic agents.

Abstract translation: 本发明涉及包含芳香酶抑制剂4,4'[氟 - （1-H-1,2,4-三唑-1-基）亚甲基]双苄腈作为合适载体中活性成分的低剂量药物组合物。 本发明还涉及其制备方法及其作为治疗剂的用途。